Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems

Climacteric

Volumn 2, Issue 4, 1999, Pages 248-253

  Buch, A B ^a   Shen, L Z ^a   Kelly, S C ^a   Russell, D A ^a   Sahota, R S ^b   Bixler, C A ^a   Moehrke, W ^b   Powell, J H ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b Clin Pharmacol/Pharmacokinetics ^*

Author keywords

Alora ; Bioavailability; Estrogen replacement Therapy; Evorel ; Pharmacokinetics; Transdermal estradiol

Indexed keywords

ESTRADIOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN THERAPY; FEMALE; HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

EID: 0033399615     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139909038084     Document Type: Article

References (26)

1. 1. Thorneycroft IH. Practical aspects of hormone replacement therapy. Prog Cardiovasc Dis 1995; 38:243-55
2. 2. Spencer CS, Cooper A, Stevenson J. Management of the menopause with HRT. Prescriber 1996;5 October:69-87
3. 3. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biological effects of transdermal estradiol. N Engl J Med 1986;314:1615-20
4. 4. Adami S, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 1993;17:191-6
5. 5. Samaan SA, Crawford MH. Estrogen and cardiovascular function after menopause. J Am Coll Cardiol 1995;26:1403-10
6. 6. Limouzin-Lamothe M-A, Mairon N, Joyce CRB, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;179:618-24
7. 7. Balfour JA, Heel RC. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;4:561-82
8. 8. Campagnoli C, Lesca L, Cantamessa C, Peris C. Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings. Maturitas 1993;18:21-46
9. 9. Judd HL. Transdermal estradiol. A potentially improved method of hormone replacement. J Reprod Med 1994;39:343-52
10. 10. Youngkin EQ. Estrogen replacement therapy and the Estraderm transdermal system. Nurse Practitioner 1990;15:19-31
11. 11. Corson SL. Clinical experience with Systen, a new transdermal form of hormone replacement therapy. Int J Fertil 1993;38:36-44
12. 12. Good WR, John VA, Ramirez M, Higgins JE, on behalf of Alora Study Group. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora™) versus placebo in postmenopausal women experiencing menopausal symptoms. Clin Ther 1996;18:1093-105
13. 13. Gordon SF. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Am J Obstet Gynecol 1995; 173:998-1004
14. 14. Marty JP. New trends in transdermal technologies: development of the skin patch, Menorest®. Int J Gynecol Obstet 1996;52:S1-20
15. 15. Ross D, Rees M, Godfree V, et al. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. Br Med J 1997; 315:288
16. 16. Al-Azzawi F, van der Mooren MJ, Rolland R, Hirvonen E, Lyrelle Study Group. A randomised study to compared the efficacy and safety of a new 17β-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomized postmenopausal women. Br J Clin Pract 1997;51: 20-6
17. 17. Bowen AJ, John VA, Ramirez ME, Good WR. Bioavailability of oestradiol from the Alora (0.1 mg/day) oestradiol matrix delivery system compared with Estraderm (0.1 mg/day). J Obstet Gynaecol 1998;18:575-80
18. 18. Buch AB, Shen LZ, Kelly SC, et al. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara. Menopause 1998;5:107-12
19. 19. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 1982
20. 20. Corson SL. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacological and clinical findings. Int J Fertil 1993;38:79-91
21. 21. Brennan JJ, Nolan JC, Hui J, et al. Lowest effective plasma concentration ranges of estrogen that prevent bone mineral density loss in postmenopausal women receiving esterified estrogens. Clin Pharm Ther 1997;61:168
22. 22. Ribot C, Tremollieres F, Pouilles JM, Louvet JP, Peyron R. Preventive effects of transdermal administration of 17β-estradiol on postmenopausal bone loss: a 2-year prospective study. Gynecol Endocrinol 1989;3:259-67
23. 23. Reginster JY, Christiansen C, Dequinze B, et al. Effect of transdermal 17β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Calcif Tissue Int 1993;53:13-16
24. 24. Blacker C, Brion N, Caulin F, et al. Plasma concentration of estradiol after transdermal administration of Systen® 50 (Evorel®) or Menorest® 50. Clin Drug Invest 1996;11:339-46
25. 25. Guichard JP, Sauron R, Duterte JP, Tanner T, Woodward AJ, Dewland PM. A pilot study of the comparative bioavailability of estradiol from two different estradiol transdermal systems: Oesclim® 5-and Systen® 50. Curr Ther Res 1996;56: 1022-32
26. 26. Reginster JY, Albert A, Deroisy R, et al. Plasma estradiol concentrations and pharmacokinetics following transdermal administration of Menorest 50 or Systen (Evorel) 50. Maturitas 1997; 27:179-86